国产吸附破伤风疫苗用于成人加强免疫的安全性及免疫原性观察
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:


Safety and immunogenicity of booster dose of adsorbed tetanus vaccine in adults
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:评价成都欧林生物科技股份有限公司研制的吸附破伤风疫苗用于成人加强免疫的临床安全性与免疫原性。方法:分两阶段开展:第一阶段采用开放性设计,评价试验疫苗的安全性,在确认安全性的情况下开展第二阶段试验;第二阶段采用单中心-随机-盲法-同类制品平行对照的试验设计,选择18~30岁的常住健康人群,按1∶1的比例随机接种试验疫苗和阳性对照疫苗,使用日记卡记录接种后28 d内的不良反应/事件发生情况。采集免疫前和免疫后28 d的血液标本,使用标准酶联免疫吸附试验方法进行破伤风类毒素抗体浓度检测。结果:第一阶段招募30名受试者,试验疫苗接种后7 d内总体不良反应为33.3%;第二阶段试验组和阳性对照组各入组600人,总体不良反应发生率分别为30.7%和31.5%,以轻中度不良反应为主,最常见接种局部和全身不良反应分别为疼痛和发热,不良反应的发生在组间差异无统计学意义(P ≥ 0.05)。加强免疫后试验组与阳性对照组均诱导较强的免疫反应:破伤风抗体浓度达到保护性水平的受试者比例均达到100%,GMC分别为3.38-3.16 U/ml。结论:成都欧林生物科技股份有限公司研制的吸附破伤风疫苗具有良好的安全性和免疫原性,适用于成人进行加强免疫和进一步进行联合疫苗的研制。

    Abstract:

    Objective: To evaluate the safety and immunogenicity of booster immunization of adsorbed tetanus vaccine developed by Olymvax Biological Technology co., LTD in adults. Methods: This study was divided into two phases. For the first phase, openly design was adopted to evaluate the safety of experimental vaccine and the second phase would be performed if the vaccine was confirmed to be safety. The second phase of this study was designed to be a single center, randomized, double-blinded, paralleled controlled clinical trial. Health residents aged 18 to 30 years old were recruited to receive one dose of experimental adsorbed tetanus vaccine and control vaccine. Daily diary was used to collect safety data. Blood samples were collected right before and 28 days after vaccination for Tetanus toxoid antibody detection through standard enzyme linked immunosorbent assay. Results: Thirty participants were enrolled in the first phase of clinical trial. Frequency of total adverse reactions (AR) observed within 7 days after vaccination was 33.3%. In the second phase of clinical trial,1 200 participants were enrolled with 600 participants in experimental vaccine and control group, respectively. Incidences of total AR were 30.7% and 31.5% for vaccine and control group, respectively. Most common injection-site AR was pain, while most common systemic AR was fever. No statistically significant differences of frequencies of AR were found between treatment groups. For both group, good immunological response was induced, with proportion of participants with antibody concentration ≥0.1 U/ml for both groups up to 100% and GMCs were 3.38 U/ml and 3.16 U/ml, respectively. Conclusion: Adsorbed tetanus vaccine developed by Olymvax Biological Technology co., LTD showed good safety and immunogenicity, which is applicable for booster immunization for adults, and for further developing of combined vaccine.

    参考文献
    相似文献
    引证文献
引用本文

梁 祁,戴启刚,顾晟年,王诗远,李洪光,彭志行,胡月梅.国产吸附破伤风疫苗用于成人加强免疫的安全性及免疫原性观察[J].南京医科大学学报(自然科学版),2015,(1):51-57

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2014-05-12
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2015-02-06
  • 出版日期:
通知关闭
郑重声明